ArticleInternational journal of peptide research and therapeutics2006
The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.
Article in International journal of peptide research and therapeutics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 88 citations in OpenAlex.
- Filamentous Phage for Therapeutic Applications in Non-Small Cell Lung Cancer and Brain Metastases: Recent Prospect.International journal of nanomedicine · 2026Review
- Review
- Developing New Peptides and Peptide-Drug Conjugates for Targeting the FGFR2 Receptor-Expressing Tumor Cells and 3D Spheroids.Biomimetics (Basel, Switzerland) · 2024Article
- Designer Small-Molecule Control System Based on Minocycline-Induced Disruption of Protein-Protein Interaction.ACS chemical biology · 2024Article
- Discovery and characterization of anti-cancer peptides from a random peptide library.PloS one · 2024Article
- CD47Binder: Identify CD47 Binding Peptides by Combining Next-Generation Phage Display Data and Multiple Peptide Descriptors.Interdisciplinary sciences, computational life sciences · 2023Article
- Identification of a novel peptide targeting TIGIT to evaluate immunomodulation ofFrontiers in oncology · 2023Article
- The translational paradigm of nanobiomaterials: Biological chemistry to modern applications.Materials today. Bio · 2022Review
- Novel Regioselective Approach to Cyclize Phage-Displayed Peptides in Combination with Epitope-Directed Selection to Identify a Potent Neutralizing Macrocyclic Peptide for SARS-CoV-2.ACS chemical biology · 2022Article
- Phage ImmunoPrecipitation Sequencing (PhIP-Seq): The Promise of High Throughput Serology.Pathogens (Basel, Switzerland) · 2022Review
- A Dodecapeptide Selected by Phage Display as a Potential Theranostic Probe for Colon Cancers.Translational oncology · 2020Article
- B1.12: a novel peptide interacting with the extracellular loop of the EBV oncoprotein LMP1.Scientific reports · 2019Article
- Identification of a specific peptide binding to colon cancer cells from a phage-displayed peptide library.British journal of cancer · 2018Article
- Paradigm shift in bacteriophage-mediated delivery of anticancer drugs: from targeted 'magic bullets' to self-navigated 'magic missiles'.Expert opinion on drug delivery · 2017Review
- A new approach to quantification of mAb aggregates using peptide affinity probes.Scientific reports · 2017Article
- Selection of antitumor displayed peptides for the specific delivery of the anticancer drug lactaptin.Oncology letters · 2016Article
- Advancement and applications of peptide phage display technology in biomedical science.Journal of biomedical science · 2016Article
- Paclitaxel-loaded PEG-PE-based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and efficiently reduce tumors.Molecular cancer therapeutics · 2014Article
- Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infection.World journal of gastroenterology · 2014Review
- Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines.Protein engineering, design & selection : PEDS · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies have been successfully utilized as cancer-targeting therapeutics and diagnostics, but the efficacies of these treatments are limited in part by the size of the molecules and non-specific uptake by the reticuloendothelial system. Peptides are much smaller molecules that can specifically target cancer cells and as such may alleviate complications with antibody therapy. Although many endogenous and exogenous peptides have been developed into clinical therapeutics, only a subset of these consists of cancer-targeting peptides. Combinatorial biological libraries such as bacteriophage-displayed peptide libraries are a resource of potential ligands for various cancer-related molecular targets. Target-binding peptides can be affinity selected from complex mixtures of billions of displayed peptides on phage and further enriched through the biopanning process. Various cancer-specific ligands have been isolated by in vitro, in vivo, and ex vivo screening methods. As several peptides derived from phage-displayed peptide library screenings have been developed into therapeutics in current clinical trials, which validates peptide-targeting potential, the use of phage display to identify cancer-targeting therapeutics should be further exploited.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.